Justice Department Briefing 2026-08-12

Estimated reading time: 2 minutes

1. Agency Information Collection Activities; Proposed eCollection eComments Requested; New Information Collection; USAO-PR COMMUNITY OUTREACH REQUEST FORM Feedback Form Package

Link: https://www.federalregister.gov/documents/2026/08/12/2026-16437/agency-information-collection-activities-proposed-ecollection-ecomments-requested-new-information

Sub: Justice Department

Content: The USAO-PR, Department of Justice (DOJ), will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995.

2. Schedules of Controlled Substances: Temporary Placement of O-Desmethyltramadol in Schedule I

Link: https://www.federalregister.gov/documents/2026/08/12/2026-16413/schedules-of-controlled-substances-temporary-placement-of-o-desmethyltramadol-in-schedule-i

Sub: Justice Department, Drug Enforcement Administration

Content: The Drug Enforcement Administration issues this temporary order to schedule O-desmethyltramadol (other names: O-DSMT; desmetramadol; 3-[(1R,2R)-2-[(dimethylamino)methyl]-1- hydroxycyclohexyl]phenol), including its isomers, esters, ethers, salts, and salts of isomers, esters and ethers, in schedule I of the Controlled Substances Act. DEA bases this action on a finding that placing O-DSMT in schedule I is necessary to avoid an imminent hazard to public safety. This order imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle O-DSMT.


Legal Disclaimer

This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.